Ergomed Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Ergomed şirketinin toplam hissedar öz sermayesi £84.7M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £129.3M ve £44.6M dir. Ergomed 'in FAVÖK'ü £20.5M faiz karşılama oranı 33.5 dur. Şirketin £19.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	33.5x
Nakit	UK£19.10m
Eşitlik	UK£84.75m
Toplam yükümlülükler	UK£44.60m
Toplam varlıklar	UK£129.35m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2EM 'nin kısa vadeli varlıkları ( £58.2M ) kısa vadeli yükümlülüklerini ( £38.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2EM şirketinin kısa vadeli varlıkları ( £58.2M ) uzun vadeli yükümlülüklerini ( £5.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2EM borçsuzdur.

Borcun Azaltılması: 2EM un 5 yıl önce borcu yoktu.

Borç Kapsamı: 2EM un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 2EM şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Ergomed Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Ergomed Confirms Expected Scheme Timetable

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc, Annual General Meeting, Jun 22, 2023

Full year 2022 earnings released: EPS: UK£0.30 (vs UK£0.26 in FY 2021)

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Now 21% undervalued after recent price drop

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Ergomed plc, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Now 21% undervalued

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Investor sentiment improved over the past week

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Investor sentiment improved over the past week

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Investor sentiment improved over the past week

Full year 2020 earnings released

New 90-day high: €14.15

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €13.40

New 90-day high: €12.10

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

New 90-day high: €9.76

New 90-day high: €9.58

New 90-day high - €7.68

New 90-day high - €6.86

Ergomed plc to Report First Half, 2020 Results on Sep 22, 2020

New 90-day high - €6.60

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin